Search for a trial

Phase II and Pharmacological Study with Wee-1 inhibitor AZD1775 Combined with Carboplatin in Patients with p53 Mutated Epithelial Ovarian Cancer that Show Early Relapse (<3 months) or Progression during Standard First Line Treatment with Carboplatin - Paclitaxel Combination Therapy. With an additional safety and preliminary anti-tumor activity cohort of Wee-1 inhibitor AZD1775 Combined with Carboplatin in Patients with p53 Mutated Epithelial Ovarian Cancer, non-small cell lung cancer (NSCLC), sm

Objective of the phase II POP study:To determine the safety and preliminary anti-tumor activity of AZD1775 in combination with carboplatin in p53 mutated epithelial ovarian cancer in a 21 day schedule.Objectives of the additional safety and…